FLINT, Mich., Aug. 15, 2017 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO), is now dispensing opioid-overdose
antidote naloxone to Michigan
residents.
Naloxone is available without a prescription at Diplomat's
Flint retail pharmacy, G-3320
Beecher Road.
Naloxone, approved by the Food and Drug Administration, is
intended to block or reverse the effects of opioid-related
drugs—including extreme drowsiness, slowed breathing, and loss of
consciousness. The medication is often carried by first responders
and caregivers of people with heroin addiction.
"Protecting the health and safety of our patients is what we
do," said Gary Rice, executive vice
president of operations at Diplomat. "We are committed to providing
access to lifesaving medication like naloxone in the communities we
serve."
According to the Centers for Disease Control and Prevention,
more than 1,000 Americans per day are treated in emergency
departments for misusing prescription opioids.
The Michigan Department of Health and Human Services issued a
standing order in May to allow pharmacists to generate naloxone
prescriptions for eligible people. The order aims to ensure those
at risk of overdose or those in a position to assist such a person
can quickly obtain naloxone.
For a list of Michigan
pharmacies approved to dispense naloxone, visit
michigan.gov/mdhhs.
Naloxone should not be used in place of emergency medical care
for an overdose.
To learn more about Diplomat, visit diplomat.is.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended Dec. 31,
2016, and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's largest independent
provider of specialty pharmacy services—helping patients and
providers in all 50 states. The company offers medication
management programs for people with complex chronic diseases and
delivers unique solutions for manufacturers, hospitals, payors,
providers, and more. Diplomat opened its doors in 1975 as a
neighborhood pharmacy with one essential tenet: "Take good care of
patients and the rest falls into place." Today, that tradition
continues—always focused on improving patient care and clinical
adherence. For more information, visit diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
View original content with
multimedia:http://www.prnewswire.com/news-releases/diplomat-dispensing-opioid-overdose-antidote-naloxone-300504851.html
SOURCE Diplomat Pharmacy, Inc.